Selecta biosciences, inc (SELB)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Jan'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Dec'15
Assets
Current assets:
Cash, cash equivalents, and restricted cash

-

-

34,513

30,479

32,452

-

50,485

60,237

58,304

70,698

70,698

-

-

-

-

-

-

-

Cash and cash equivalents

72,606

89,893

-

-

-

37,403

-

-

-

-

-

72,151

82,630

26,637

58,656

59,488

82,648

32,337

Restricted cash

279

279

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Short-term deposits and investments

-

-

-

11,500

16,200

-

0

5,991

24,839

25,940

25,940

32,237

30,025

41,885

25,485

19,788

1,900

4,125

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

76

74

81

78

335

407

133

Accounts receivable

0

5,000

-

-

-

0

-

-

52

-

-

0

1

63

215

483

1,961

824

Prepaid expenses and other current assets

1,555

1,495

1,606

2,490

10,832

4,673

5,083

2,607

1,789

2,042

2,042

2,888

1,848

2,820

2,382

3,303

2,131

1,494

Total current assets

74,440

96,667

36,119

44,449

59,528

42,076

55,568

68,835

84,984

98,680

98,680

107,352

114,578

71,486

86,816

83,397

89,047

38,913

Property, Plant and Equipment, Net

1,134

1,222

1,452

1,620

1,799

2,127

2,109

2,137

2,257

2,091

2,091

2,055

2,131

2,054

2,047

2,066

1,954

2,029

Operating Lease, Right-of-Use Asset

11,847

301

594

878

1,155

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term restricted cash

1,379

1,379

1,379

0

0

279

2,646

2,465

2,696

329

329

316

316

316

316

316

316

316

Other assets

-

-

-

-

-

-

-

-

-

-

-

0

0

0

122

0

-

1,566

Total assets

88,800

99,569

39,544

46,947

62,482

44,482

60,323

73,437

89,937

101,100

101,100

109,723

117,025

73,856

89,301

85,779

91,317

42,824

Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable

1,330

500

1,478

2,463

693

1,100

1,252

1,789

1,789

1,606

1,606

1,519

4,280

1,317

3,882

1,040

943

2,179

Accrued Liabilities, Current

8,775

13,492

5,316

5,789

8,500

11,700

10,218

10,184

9,062

8,580

8,580

6,547

8,595

5,521

3,921

2,434

4,715

3,378

Deferred revenue, current portion

-

-

-

-

-

-

-

-

959

-

-

-

-

-

-

-

-

-

Loan payable

16,868

18,905

20,927

21,548

21,466

21,385

21,299

-

-

-

0

0

4,612

4,519

4,067

2,913

1,781

0

Operating Lease, Liability, Current

1,425

372

734

1,085

1,428

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

1,674

1,674

1,023

1,023

959

959

1,863

1,918

-

787

787

-

-

-

-

-

-

-

Deferred revenue, current portion

-

-

-

-

-

-

-

-

-

-

-

3,256

2,566

1,947

1,836

1,041

1,242

1,313

Contingently repayable grant funding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

262

258

420

Total current liabilities

30,072

34,943

29,478

31,908

33,046

35,144

34,632

13,891

11,810

10,973

10,973

11,322

20,053

13,304

13,706

7,690

8,939

7,290

Non‑current liabilities:
Operating Lease, Liability, Noncurrent

10,440

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and lease incentive

-

-

-

-

0

-

67

98

129

151

151

168

189

210

222

234

-

105

Loan payable, net of current portion

-

-

-

-

-

-

0

21,212

21,127

21,042

21,042

20,954

5,732

6,867

7,977

9,064

10,128

11,855

Deferred revenue

14,656

14,680

14,981

14,983

13,816

13,818

13,824

12,870

-

14,089

15,919

-

-

-

-

-

-

-

Warrant liabilities

42,395

41,549

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

13,917

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

-

-

-

10,953

11,619

12,385

12,439

3,348

3,474

2,295

Other long‑term liabilities

-

-

0

0

801

938

1,800

1,104

1,372

1,201

1,201

1,250

1,250

-

0

0

-

290

Total liabilities

97,563

91,172

44,459

46,891

47,663

49,900

50,323

49,175

48,355

47,456

49,286

44,647

38,843

32,766

34,344

20,336

22,541

21,835

Commitments and contingencies (Note 17)

-

-

-

-

-

-

0

0

0

-

-

0

0

0

0

0

0

0

Total redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

137,482

Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

0

0

0

0

0

0

0

0

0

-

0

0

0

0

0

0

0

0

Common stock, $0.0001 par value; 200,000,000 shares authorized; 87,019,172 and 86,325,547 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

9

9

5

5

5

3

3

3

3

3

3

2

1

1

1

1

1

0

Additional paid-in capital

351,184

348,664

320,478

313,447

311,824

279,539

277,721

275,888

274,334

273,128

273,128

266,836

265,297

212,249

211,125

207,489

203,125

1

Receivable from stock option exercises

-

-

-

-

-

-

53

-

-

-

-

0

26

70

75

-

-

0

Retained Earnings (Accumulated Deficit)

-355,400

-335,753

-320,900

-308,900

-292,500

-280,400

-263,154

-247,153

-228,357

-215,067

-216,897

-197,353

-182,677

-166,710

-151,576

-137,493

-129,765

-111,508

Accumulated other comprehensive loss

-4,583

-4,523

-4,533

-4,525

-4,533

-4,557

-4,517

-4,476

-4,398

-4,420

-4,420

-4,409

-4,413

-4,380

-4,518

-4,554

-4,585

-4,986

Stockholders' Equity Attributable to Parent

-8,763

8,397

-4,915

56

14,819

-5,418

10,000

24,262

41,582

53,644

51,814

65,076

78,182

41,090

54,957

65,443

68,776

-116,493

Total liabilities and stockholders’ equity (deficit)

88,800

99,569

39,544

46,947

62,482

44,482

60,323

73,437

89,937

101,100

101,100

109,723

117,025

73,856

89,301

85,779

91,317

42,824